Verena Materna

1.4k total citations
33 papers, 1.1k citations indexed

About

Verena Materna is a scholar working on Oncology, Molecular Biology and Reproductive Medicine. According to data from OpenAlex, Verena Materna has authored 33 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 13 papers in Molecular Biology and 9 papers in Reproductive Medicine. Recurrent topics in Verena Materna's work include Drug Transport and Resistance Mechanisms (13 papers), Ovarian cancer diagnosis and treatment (9 papers) and Cancer Cells and Metastasis (6 papers). Verena Materna is often cited by papers focused on Drug Transport and Resistance Mechanisms (13 papers), Ovarian cancer diagnosis and treatment (9 papers) and Cancer Cells and Metastasis (6 papers). Verena Materna collaborates with scholars based in Germany, Poland and Hungary. Verena Materna's co-authors include Hermann Lage, Paweł Surowiak, M. Zabel, Manfred Dietel, Marek Spaczyński, Bernd Liedert, Jürgen Thomale, Marek Pudełko, Adam Maciejczyk and Dirk Schadendorf and has published in prestigious journals such as Clinical Cancer Research, Biochemical and Biophysical Research Communications and British Journal of Cancer.

In The Last Decade

Verena Materna

33 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Verena Materna Germany 20 632 552 220 155 116 33 1.1k
David H. Moore United States 15 411 0.7× 647 1.2× 237 1.1× 118 0.8× 39 0.3× 34 1.3k
Adam Maciejczyk Poland 17 380 0.6× 371 0.7× 176 0.8× 45 0.3× 68 0.6× 85 915
Maree Bilandzic Australia 17 351 0.6× 391 0.7× 157 0.7× 196 1.3× 60 0.5× 29 884
D L Baly United States 15 1.2k 1.8× 720 1.3× 246 1.1× 40 0.3× 176 1.5× 20 2.0k
Shona Nag India 13 720 1.1× 228 0.4× 217 1.0× 67 0.4× 43 0.4× 34 1.0k
R F Ozols United States 17 723 1.1× 606 1.1× 123 0.6× 243 1.6× 34 0.3× 29 1.4k
G L Scheffer Netherlands 13 1.3k 2.0× 780 1.4× 96 0.4× 72 0.5× 69 0.6× 14 1.7k
Laura M. Handel United States 11 335 0.5× 444 0.8× 100 0.5× 208 1.3× 46 0.4× 13 812
Eleonora Petrucci Italy 22 358 0.6× 856 1.6× 387 1.8× 84 0.5× 24 0.2× 35 1.6k
F. Javier Carmona Spain 18 262 0.4× 1.1k 2.0× 478 2.2× 56 0.4× 35 0.3× 25 1.6k

Countries citing papers authored by Verena Materna

Since Specialization
Citations

This map shows the geographic impact of Verena Materna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Verena Materna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Verena Materna more than expected).

Fields of papers citing papers by Verena Materna

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Verena Materna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Verena Materna. The network helps show where Verena Materna may publish in the future.

Co-authorship network of co-authors of Verena Materna

This figure shows the co-authorship network connecting the top 25 collaborators of Verena Materna. A scholar is included among the top collaborators of Verena Materna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Verena Materna. Verena Materna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hałoń, Agnieszka, Verena Materna, Piotr Donizy, et al.. (2012). MRP2 (ABCC2, cMOAT) expression in nuclear envelope of primary fallopian tube cancer cells is a new unfavorable prognostic factor. Archives of Gynecology and Obstetrics. 287(3). 563–570. 12 indexed citations
2.
Hałoń, Agnieszka, Verena Materna, Małgorzata Drąg‐Zalesińska, et al.. (2011). Estrogen Receptor Alpha Expression in Ovarian Cancer Predicts Longer Overall Survival. Pathology & Oncology Research. 17(3). 511–518. 46 indexed citations
3.
Hałoń, Agnieszka, Verena Materna, Grzegorz Mazur, et al.. (2011). Elevated YB-1 expression is a new unfavorable prognostic factor in non-Hodgkin's lymphomas.. PubMed. 31(9). 2963–70. 15 indexed citations
4.
Surowiak, Paweł, Verena Materna, Adam Maciejczyk, et al.. (2007). Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 450(3). 279–285. 66 indexed citations
5.
Surowiak, Paweł, Verena Materna, Marek Spaczyński, et al.. (2006). ABCC2 (MRP2, cMOAT) Can Be Localized in the Nuclear Membrane of Ovarian Carcinomas and Correlates with Resistance to Cisplatin and Clinical Outcome. Clinical Cancer Research. 12(23). 7149–7158. 87 indexed citations
6.
Surowiak, Paweł, Verena Materna, Małgorzata Drąg‐Zalesińska, et al.. (2006). Maspin Expression Is Characteristic for Cisplatin-Sensitive Ovarian Cancer Cells and for Ovarian Cancer Cases of Longer Survival Rates. International Journal of Gynecological Pathology. 25(2). 131–139. 19 indexed citations
7.
Surowiak, Paweł, Verena Materna, Marek Spaczyński, et al.. (2006). Topoisomerase 1A, HER/2neu and Ki67 expression in paired primary and relapse ovarian cancer tissue samples.. PubMed. 21(7). 713–20. 20 indexed citations
8.
Surowiak, Paweł, Verena Materna, Rafał Matkowski, et al.. (2006). CD24 expression is specific for tamoxifen-resistant ductal breast cancer cases.. PubMed. 26(1B). 629–34. 16 indexed citations
9.
Surowiak, Paweł, Marcin Drąg, Verena Materna, et al.. (2006). Expression of aminopeptidase N/CD13 in human ovarian cancers. International Journal of Gynecological Cancer. 16(5). 1783–1788. 41 indexed citations
10.
Győrffy, Balázs, Violeta Serra, Verena Materna, et al.. (2006). Analysis of gene expression profiles in melanoma cells with acquired resistance against antineoplastic drugs. Melanoma Research. 16(2). 147–155. 8 indexed citations
11.
Surowiak, Paweł, Verena Materna, Balázs Győrffy, et al.. (2006). Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers. British Journal of Cancer. 95(3). 339–346. 44 indexed citations
12.
Rompe, Franziska, Holger Tönnies, Paweł Surowiak, et al.. (2006). Complete Reversal of ABCG2-Depending Atypical Multidrug Resistance by RNA Interference in Human Carcinoma Cells. Oligonucleotides. 16(3). 263–274. 23 indexed citations
13.
Surowiak, Paweł, Verena Materna, Manfred Dietel, et al.. (2006). Unfavorable prognostic value of CD24 expression in sections from primary and relapsed ovarian cancer tissue. International Journal of Gynecological Cancer. 16(2). 515–521. 16 indexed citations
14.
Surowiak, Paweł, Verena Materna, Rafał Matkowski, et al.. (2005). Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Research. 7(5). R862–70. 69 indexed citations
15.
Surowiak, Paweł, Verena Materna, Carsten Denkert, et al.. (2005). Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers. Cancer Letters. 235(2). 272–280. 34 indexed citations
16.
Materna, Verena, Bernd Liedert, Jürgen Thomale, & Hermann Lage. (2005). Protection of platinum–DNA adduct formation and reversal of cisplatin resistance by anti‐MRP2 hammerhead ribozymes in human cancer cells. International Journal of Cancer. 115(3). 393–402. 69 indexed citations
17.
Surowiak, Paweł, Rafał Matkowski, Verena Materna, et al.. (2005). Elevated metallothionein (MT) expression in invasive ductal breast cancers predicts tamoxifen resistance.. PubMed. 20(4). 1037–44. 29 indexed citations
18.
Materna, Verena & Hermann Lage. (2003). Homozygous mutation Arg768Trp in the ABC-transporter encoding gene MRP2/cMOAT/ABCC2 causes Dubin-Johnson syndrome in a Caucasian patient. Journal of Human Genetics. 48(9). 484–486. 16 indexed citations
19.
Liedert, Bernd, Verena Materna, Dirk Schadendorf, Jürgen Thomale, & Hermann Lage. (2003). Overexpression of cMOAT (MRP2/ABCC2) Is Associated with Decreased Formation of Platinum-DNA Adducts and Decreased G2-Arrest in Melanoma Cells Resistant to Cisplatin. Journal of Investigative Dermatology. 121(1). 172–176. 102 indexed citations
20.
Materna, Verena, Per Sonne Holm, Manfred Dietel, & Hermann Lage. (2001). Kinetic characterization of ribozymes directed against the cisplatin resistance–associated ABC transporter cMOAT/MRP2/ABCC2. Cancer Gene Therapy. 8(3). 176–184. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David H. Moore Breakdown of academic impact, for papers by Adam Maciejczyk Breakdown of academic impact, for papers by Maree Bilandzic Breakdown of academic impact, for papers by D L Baly Breakdown of academic impact, for papers by Shona Nag Breakdown of academic impact, for papers by R F Ozols Breakdown of academic impact, for papers by G L Scheffer Breakdown of academic impact, for papers by Laura M. Handel Breakdown of academic impact, for papers by Eleonora Petrucci Breakdown of academic impact, for papers by F. Javier Carmona
Rankless by CCL
2026